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Abstract: Strategies to prevent cancer and diagnose it early when it is
most treatable are needed to reduce the public health burden from rising
disease incidence. Risk assessment is playing an increasingly important role
in targeting individuals in need of such interventions. For breast cancer
many individual risk factors have been well understood for a long time,
but the development of a fully comprehensive risk model has not been
straightforward, in part because there have been limited data where joint
effects of an extensive set of risk factors may be estimated with precision. In
this article we first review the approach taken to develop the IBIS (Tyrer-
Cuzick) model, and describe recent updates. We then review and develop
methods to assess calibration of models such as this one, where the risk
of disease allowing for competing mortality over a long follow-up time or
lifetime is estimated. The breast cancer risk model model and calibration
assessment methods are demonstrated using a cohort of 132 139 women
attending mammography screening in Washington, USA.
Keywords and phrases: Breast cancer, Calibration, Risk assessment,
Breast density, Tyrer-Cuzick model, IBIS model.
MSC 2010 subject classifications: Primary: Statistics (62); Secondary:
Research exposition (62-02), Survival analysis and censored data (62N01),
Applications to biology and medical science (62P10).
1. Introduction
Unlike lung cancer (tobacco smoking) and cervix cancer (persistent infection
with the human papilloma virus) where a single factor explains the majority
of the cases, a large number of factors have been found to be important for
determining the risk of breast cancer. An increased risk in women with a family
history appears to have been known in ancient Roman times [58], and in 1842
Rigoni-Stern reported that nuns had an increased risk of breast cancer [52, 23],
paving the way for further research which established that not having a child or
having a first childbirth at an older age increased the risk of this disease. Much of
the modern work on risk factors was done by Macmahon and colleagues, mostly
at Harvard [42]. Pike and colleagues emphasized the link with oestrogens and
proposed that much of the population risk could explained by a computing the
cumulative lifetime exposure to oestrogens based mostly on age at menarche,
childbearing history and age at menopause [48]; an important meta-analysis and
update on these and other factors was provided by Beral and colleagues [46].
1
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In 1976 Wolfe discovered that breast density was another key risk factor that
was broadly unrelated to the known classical factors, but of roughly equal impor-
tance in their combined predictive value [68]. This has been further developed
by Boyd [11, 10], McCormack and others [44]. In the same paper Wolfe also
suggested [68] using breast density for risk assessment to determine how best to
use mammography for breast cancer screening. Several decades later, advances
in the ability to accurately stratify women into higher and lower-risk groups are
likely to move early detection strategies towards this vision, and replace ‘one-
size-fits-all’ screening with so-called ‘risk-adapted’ programs in which both the
frequency with which a woman is screened and the modality are chosen based
on the risk of breast cancer. Motivations include the identification of women at
extremely high risk, who are potential candidates for risk-reducing surgery or
preventive therapy [28], delineation of a group at moderately enhanced risk who
might benefit from enhanced screening [59], and identification of populations at
sufficiently low risk so as to require less frequency or even no screening.
A number of risk models have been developed, mostly for Caucasian women
living in North America and Western Europe [31, 17, 4]. In this article we
focus on risk assessment using the Tyrer-Cuzick model [62]. This is a hybrid of
two popular sub-models often used for breast cancer risk assessment: a genetic
segregation model for familial risk that is combined with a proportional-hazards
regression model for other risk factors.
Breast cancer risk factors in the model broadly fit into five general cate-
gories: (1) family history and highly penetrant dominant genetic mutations; (2)
factors associated with oestrogen exposure, including age at first childbirth, age
at menopause and menarche (beginning of periods), use of hormone replacement
therapy, height and weight; (3) certain types of prior benign breast disease, (4)
breast imaging features seen on the mammogram - notably the amount of dense
tissue (opaque areas on a mammogram or breast x-ray); and (5) common but
individually less penetrant genetic differences (single nucleotide polymorphisms,
SNPs), where several hundred relatively common genetic variants that individ-
ually have a small impact on disease have been identified, and that jointly make
an important contribution to overall risk assessment via a ‘polygenic risk score’
[43]. There are also some other apparent risk factors which are harder to quan-
tify, but which may improve the performance of the model.
In the rest of this paper we outline the statistical basis of our model, review
and develop methods to assess model calibration that include competing mor-
tality (which has been handled differently in different papers), and apply our
model and calibration assessment methods to data from a large cohort of women
attending mammographic screening in Washington, USA.
2. Breast cancer risk assessment
2.1. Background
To provide an assessment of the risk of disease occurring within a person’s
residual lifetime it is important to take into account competing risks that could
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lead to death from other causes. In a classical ‘latent lifetimes’ framework [19]
each individual is subject to m potential causes of death with times Tj (j =
1, . . . ,m) and we observe their actual time of death T˜ = min(T1, . . . , Tm) and
the specific cause J = 1, . . . ,m. This framework assumes that each death is
attributable to a single cause, or a defined group of causes. We extend this
approach to also include the incidence of breast cancer, which is our principle
interest, and do not consider death after breast cancer occurs.
Multiple modes of failure are conveniently characterised using functions for
the rate at which each cause J occurs at each follow-up time, given that the per-
son has not yet died, or experienced a specific event of interest. More precisely,
this cause-specific hazard for j = 1, . . . ,m is defined as
hj(t) = lim
∆→0
P(Tj < t+∆ | T˜ ≥ t)
∆
. (1)
Equation (1) is estimable due to conditioning on (T˜ ≥ t). Another measure
of risk that is sometimes considered is the proportion of the population who
have event J when followed up to time t. This cumulative incidence function is
defined by
P(J = j, T˜ ≤ t) =
∫ t
0
hj(u)S(u)du, (2)
where
S(t) = P(T˜ > t)
= exp
{
−
∫ t
0
m∑
k=1
hk(u)du
}
is the marginal (all-cause) survivor function for T˜ . When there is just one cause
(death, say) then (2) is the cumulative distribution function (for time of death).
Breast cancer risk models within this framework typically consider two causes
(m = 2): T1, the time to diagnosis of breast cancer and T2, the time to death
from other causes (excluding breast cancer mortality, which can’t occur before
the time of diagnosis), so that T˜ = min(T1, T2). Risk assessment for a women
usually takes place when current age t0 > 20 years, and the aim is to assess
the absolute risk of breast cancer between age t0 to age t, conditional on q risk
factors x = (x1, . . . , xq). This may be done by extending (2) to condition on
risk factors x and age at risk assessment t0 through:
P(J = 1, T˜ ≤ t | x, T˜ > t0) =
∫ t
t0
h1(u | x)exp
[
−
∫ u
t0
{h1(v | x) + h2(v | x)}dv
]
du
≡ Px(t0, t), (3)
where h1(t | x) is the conditional hazard of breast cancer at age t (c.f. equation
1) and h2(t | x) is the conditional hazard for competing mortality. In practice,
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and following [31], competing mortality has often been taken to depend only on
age and has been calibrated using national mortality statistics excluding breast
cancer incidence. This is reasonable for breast cancer, as it is not strongly linked
other causes of death, but is more problematic, e.g. for lung cancer, where
tobacco smoking is a major factor for it and other causes of death such as
cardiovascular disease.
Breast-cancer specific hazards have been estimated in two ways:
1. Regression models. Risk is frequently calculated by combination of a re-
gression model derived from case-control or cohort studies of specific rel-
ative risks combined with absolute population-based incidence rates from
cancer registries. An early and widely used example of this is the Gail
model [31], which has been further developed in the Breast Cancer Surveil-
lance Consortium (BCSC) model [15, 60, 45].
2. Estimation from family pedigree data of the probability of carrying one or
more high-risk mutations using segregation analysis, and then using the
penetrance of a mutation to alter age-specific risk [17]. Two examples are
BRCAPRO and BOADICEA [47, 4].
A novel aspect of the Tyrer-Cuzick model is that it employs both methods [62].
The segregation model estimates the hazard function hG(t | x1) at age t due
to genetic factors, conditional on information (denoted x1) about a woman’s
family history (family tree) of breast and/or ovarian cancer, and results of any
tests in the family from known highly penetrant breast cancer genes such as
BRCA1 and BRCA2. This is then combined with a relative hazard regression
function r(x2) > 0 based on other risk factors (x2) through
h1(t | x1,x2) = hG(t | x1)r(x2). (4)
We divide family history into two factors x1 = {x(a)1 ,x(b)1 } corresponding to (a)
breast and (b) ovarian cancer. The vector x
(.)
1 has components for event time,
censoring information and family relationships, and x2 is based on the other
risk factors shown in Table 1. Risk models that only account for family history
based on a segregation model do not use x2. Regression-only models developed
are often proportional-hazards models of the same form as (4), but with age-
specific population rates instead of hG(.); partial information on family history
of breast cancer can be included in the regression function, e.g. by including a
covariate for the number of affected first-degree relatives.
2.2. Tyrer-Cuzick segregation model
2.2.1. Statistical model
The genetic risk breast cancer is modelled through estimates of mutations in
BRCA1 and BRCA2 genes and an unknown dominant gene. Some of the genes
which make up the unknown component have been discovered [27], but most
have not, and are only inferred. Even the known ones are rare and individually
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do not make a major contribution, and are not so commonly tested for even in
women with a family history. We use the variable c1 for BRCA1/2 status (0 if
not a BRCA1/2 carrier, 1 if a BRCA1 carrier, and 2 if BRCA2 carrier; joint
carriers are extremely rare and are modelled as BRCA1 carriers). The unknown
dominant gene is denoted c2 (0, 1 if respectively not a carrier or a carrier). The
model makes the following assumptions.
A.i Breast x
(a)
1 and ovarian cancer x
(b)
1 family histories are conditionally in-
dependent given c1 and c2:
p(x1 | c1, c2) = p{x(a)1 | c1, c2}p{x(b)1 | c1, c2}
where p(.) is general notation to denote a probability density or mass
function.
A.ii c1 and c2 are independent: {p(c1, c2) = p(c1)p(c2)}.
A.iii The unknown gene c2 is not associated with ovarian cancer [p{x(b)1 |
c1, c2} = p{x(b)1 | c1}].
A.iv The penetrance SG(t | c1), i.e. the probability of developing disease by
age t, is known for breast and ovarian cancer in BRCA1/2 carriers. The
prevalence p(c1) of BRCA1, BRCA2 and the unknown gene are known in
the population.
A.v A proportional-hazards model is assumed for the incidence associated with
the unknown gene using two parameters θ = (β, γ) through
SG(t | c1, c2; θ) = S0(t | c1)exp(γc2) (5)
where γ quantifies the log relative hazard attributable to the unknown
gene, β is its prevalence (the per-allele proportion is 1 − √1− β), and
S0(t | c1) is a baseline survivor function. From assumption (A.iv) and
equation (5) the baseline survivor function is obtained by solving
SG(t | c1; θ) = (1− β)S0(t | c1) + βS0(t | c1)exp(γc2), (6)
e.g. via a Newton-Raphson iteration [62].
A.vi Mendelian inheritance, i.e. there is a 50% chance that one of the two alleles
from each parent is inherited by their offspring.
From these assumptions the breast cancer risk conditional on x1 is obtained as
SG(t | x1; θ) =
2∑
c1=0
1∑
c2=0
SG(t | c1, c2; θ)p(c1, c2 | x1; θ) (7)
where the weights p(c1, c2 | x1; θ) in (7) are obtained from the following appli-
cation of Bayes’ rule. Denoting d = (c1, c2) then
p(d | x1; θ) = p(x1 | d; θ)p(d; θ)
p(x1; θ)
. (8)
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p(d; θ) uses assumptions given in (A.ii, A.iv, A.v), and p(x1 | d; θ) is obtained
following A.vi (described in more detail in [62]), first separately for breast x
(a)
1
and ovarian cancer x
(b)
1 family histories and then they are combined through
(A.i). When gene testing has been done for BRCA1/2 the values for c1 are
taken from this, and the familial contribution only applied to the unknown gene
c2. Most of the computer code in the Tyrer-Cuzick algorithm is involved in
calculating the likelihood p(x1 | d; θ).
2.2.2. Parameter estimates
Some changes to the segregation model have been made since the original model
[62], starting from version 7 onwards. BRCA1/2 prevalence and penetrance are
now from the 1950+ birth cohort estimates reported in [4]. The penetrance esti-
mate is now lower than used in original model [62] (previously taken from [30]),
which was attributed in [4] to bias in the original estimate [30] resulting from a
focus on families with multiple cases of breast cancer. Prevalence of BRCA1 is
taken to be 0.06% and for BRCA2 is 0.10% (previously 0.11% and 0.12% respec-
tively). Smoothed first breast cancer rates from the Thames Registry 2005-2009
were used to calibrate overall risk, based on data reported by 5y age group
and smoothed by loess (with the smoother ‘span’ parameter 0.2 chosen by eye).
The unknown gene calibration has not been altered since the model was first
introduced (β = 11.4% and exp(γ) = 13.04, fitted to data from [3], see [62]).
The impact of the unknown gene depends mostly on the product βexp(γ) and
it is difficult to accurately estimate these two parameters separately. The best
fit gave a very large value for exp(γ) but almost equally good fits would arise if
γ was substantially reduced and β increased accordingly. Attributing risk to a
single gene is a simplification, as risk is likely to reflect a combination of genes.
However it is clear that the contribution of this unknown gene is greater than
that for BRCA1 or BRCA2, any other known gene or combination of single
nucleotide polymorphisms and treating this either as a single unknown gene or
a polygenic risk score has minimal impact on its predictive value.
2.3. Regression model
2.3.1. Model
The relative hazard r(x2) in model (4) is normalised by the mean risk in the pop-
ulation. This requires information on the relative hazard associated with other
non-familial (personal, hormonal and lifestyle) risk factors {denote this function
φ(x2) > 0} and their population prevalence {f(x2) where
∫
f(x2)dx2 = 1} in
order to obtain the normalised relative hazard
r(x2) =
φ(x2)∫
φ(x2)f(x2)dx2
. (9)
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In the Tyrer-Cuzick model this is approximated by treating each risk factor as
independent (breast cancer risk factors in the model are largely independent of
each other) and taking
r(x2) =
q∏
j=1
{
φ(x2j)∫
φ(x2j)f(x2j)dx2j
}
. (10)
When the value of a risk factor is unknown it can be left blank and the nor-
malised relative hazard associated with that factor is taken to be 1 (woman
assumed to have population risk). The mean risk constants used in the model
are shown in Table 1.
2.3.2. Parameters
The relative hazards and prevalence of risk factors in the original model were
reported in [62], and included in Table 1. There have been changes and the
current values are described below.
Atypical hyperplasia or LCIS The original model treated atypical hyper-
plasia or lobular carcinoma insitu (LCIS) as an independent risk factor.
Evidence in [25] and [9] indicated that other risk factors should not be
included when a women has been diagnosed with atypical hyperplasia as
it is more of an intermediate endpoint. As a result we modified the model
to take the maximum risk of atypical hyperplasia (only), LCIS (only) and
family history risk combined with other risk factors (based on the 10y
risk). For example, a young BRCA1/2 carrier with atypical hyperplasia
would not have her risk assessment modified by atypical hyperplasia. This
is likely to be conservative, but currently there is inadequate data to model
the joint effects of atypia and other risk factors accurately.
Unknown benign disease In general the risk of subsequent breast cancer as-
sociated with a benign lesion depends on the histology, with no increased
risk associated with non-proliferative lesions, about a two-fold risk associ-
ated with hyperplasia of the usual type and about a 4-fold risk associated
with atypical hyperplasia [26]. Based on prevalence data reported by [26],
the relative hazard from benign disease when a women has had a biopsy
but pathology is unknown is taken to be 1.3; this option was not available
originally. Non-biopsied lesions are not considered in the model.
Menopause hormone therapy The model assumes a maximum relative haz-
ard of 2.0 for combined therapy with an oestrogen and progestin and 1.4
for oestrogen-only hormone therapy. The relative hazard begins at unity
in year 1, is half the maximum excess relative hazard in year 2 and then
the maximum relative hazard therafter until stopping therapy. Risk is
then ramped down following cessation to be 2/3 of the maximum excess
in the first year after stopping, then one third in the next year, and no
increase thereafter. The relative risk is adjusted if BMI (body mass index)
is known, being decreased by 10% of the average excess risk if obese (BMI
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≥ 30 kg/m2), and increased by 10% if BMI <25 kg/m2 (not overweight or
obese). These assumptions are based on results from the Women’s Health
Initiative trial [16]) and the Million Women Study [50].
2.4. New additions to the model
2.4.1. Mammographic density
Breast density is correlated with some of the other risk factors in the model,
most strongly age and body mass index. It is also measured in different ways
that require different calibration. We allow three different ways to input den-
sity: a visual assessment in which (ideally) two readers estimate the percentage
of the breast covered by dense (opaque) tissue and the average is used, the
BI-RADS system which corresponds to four categories, and an automated vol-
umetric system (Volpara) that estimates the percentage volume of dense tissue
based on the radiographic intensity of each pixel. In order to incorporate breast
density into the model without changing the effect sizes of the other factors, we
first developed a measure of breast density which is independent from age and
BMI at mammogram, by taking the difference between observed and expected
density given age and BMI. This was developed for the different measures in
case-control studies, where expected density was modelled in controls by fitting
a generalized additive model [69] of different breast density measures against
splines for age and BMI (see Figure 1 for a fit to volumetric percent density).
The risk associated with density was then calibrated by estimating the effect of
the density residual, adjusted for other factors in the Tyrer-Cuzick model using
case-control and cohort studies [67, 14, 13].
2.4.2. Polygenic risk scores
Numerous studies have demonstrated the utility of polygenic risk scores. These
use common gene variants which individually carry small risks but as a group
provide useful information. Their utility has been observed in average risk
women [65, 45] and in high-risk women [21, 29], and they combine effectively in-
dependently with classical risk factors and breast density [63, 64]. Currently, the
breast cancer association consortium has validated more than 170 risk-modifying
SNPs at genome-wide significance [43], and this is likely to increase still further.
To provide an overall relative risk estimate from a collection of independent
SNPs polygenic risk scores may be obtained by using published data on their
per-allele risks, and allele frequencies. First the odds ratio for each of the three
SNP genotypes is determined (no risk alleles, 1 risk allele, and 2 risk alleles)
and these are normalised to obtain an average of unity using reported risk allele
frequencies. In our model we assume the odds of two copies of the abnormal
gene is the square of that for one copy, and their distribution follows the Hardy-
Weinberg law. Finally to obtain an overall polygenic risk score the odds ratios
for each of the genotypes are multiplied together assuming independence [45].
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Data show very small correlations between polygenic risk scores and classical
risk factors. We have observed that an accurate fit is obtained by treating the
score as independent of the other factors in the Tyrer-Cuzick model [21, 29, 64].
However, theoretically, a polygenic risk score will explain some of the genetic
aggregationmodelled through the segregation model, and so this should be down
weighted in the risk assessment. Work to refine this component is ongoing.
3. Comparison with other risk models
It is important to understand differences between risk models, both for use of
the models and to refine the scientific process of improving risk assessment. Here
we note some differences between the Tyrer-Cuzick and other models.
3.1. Segregation models
Some segregation models, including BRCAPRO [47], calculate breast cancer
risk only based on estimating the likelihood of carrying major genes based on a
personal and family history of breast, ovarian or other cancers related to these
genes. The main aim of such models is to estimate risk of being a BRCA1/2
mutation carrier. They are mostly used for women with a strong family history
in order to determine eligibility for BRCA1/2 testing. They incorporate both
pedigree information including age at onset and results of genetic testing for
BRCA1 and BRCA2 in the women and their relatives. Such models are less
suitable for risk assessment of breast cancer in the wider population, partly
because they do not allow for other unknown genetic factors in the model.
The BOADICEA model accounts for other rare but highly penetrant genes
(PALB2, CHEK2, ATM ), and uses a polygenic model to allow for (unobserved)
risk due to other genetic factors than those measured [41]. Define c∗1 = 0 if
not positive for one of the genes, c∗1 = 1 if test positive for BRCA1, c
∗
1 = 2 if
test positive for BRCA2 (but not BRCA1 ), c∗1 = 3 if test positive for PALB2
(but not BRCA1/2 ) and so on for next CHEK2 and last ATM. Thus very rare
individuals who test positive for more gene are assigned a group c∗1 = 0, . . . , 5
based on a hierarchy. The model has the following form for the breast cancer
specific hazard:
h1{t | c1, u(t)} = h1B(t)exp


5∑
j=1
βj(t)I(c
∗
1 = j) + u(t)

 ,
where t is age, h1B(t) is a baseline hazard function, I(.) the indicator func-
tion, βj(t) are time-dependent relative hazards for each genotype, and u(t) is a
time-dependent random effect from a normal distribution with mean zero and
standard deviation σt. When the woman has not been personally tested, the
probability of being a carrier is estimated based on the pedigree and testing
results (if any) in family members. The random (polygenic) effects arise from
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a combined effect of several unmeasured and largely unknown genes, each of
which contributes a small effect. Large scale genome-wide association studies
have identified that the polygenic model for genetic susceptibility is partly cor-
rect, but a large proportion of familial aggregation of risk is still not explained
by known major genes or polygenic risk [43].
For most pedigrees arising in the general population one might expect only
small differences for risk estimates from polygenic vs single unknown gene mod-
els. Qualitatively, the unknown single dominant gene model is a good approx-
imation to the polygenic model: the genotype is never observed and so gives
rise to a range of effects through equations (7) and (8). Indeed, one study that
compared the fit between the unknown dominant gene and polygenic models did
not show an appreciable difference between them when considering additional
genetic factors other than BRCA1/2 [5].
Another difference between BOADICEA and Tyrer-Cuzick is that the hazard
for the unknown genetic effect γ is assumed to not vary with age in the Tyrer-
Cuzick model, whereas the polygenic variance varies with age in the BOADICEA
model. Thus the BOADICEA model leads to a larger decline in the relative risk
as the age of the affected relative increases and appears to fit better with the
literature. We will update this aspect of the model in the next version.
3.2. Regression function models
Several models have been developed based on a regression function only. These
include the Gail (or BCRAT) [31], the Breast Cancer Surveillance Consortium
(BCSC) [60, 61] and Rosner-Colditz models [51, 71]. Neither the Gail nor BCSC
model include all the risk factors included in the Tyrer-Cuzick model, but they
do account for ethnic differences. The Rosner-Colditz model includes the terms
for the same broad risk factors as in the Tyrer-Cuzick model, and some ad-
ditional factors including alcohol consumption, adolescent body somatotype
(shape / size) and hormone levels. Assumptions on the risks and prevalence
of risk factors differ between the models, as do the use of interaction terms.
The Tyrer-Cuzick model includes an interaction between menopausal status
and BMI, assuming it is only a postmenopausal risk factor. Some data suggest
that BMI may actually be a protective factor for premenopausal breast cancer
but this is not included in the model [57]. Interactions are also included for BMI
and HRT (as discussed above), and atypical hyperplasia (or LCIS) and all other
risk factors in that it is treated as an intermediate endpoint, and the maximum
risk for it alone or all other factors combined is used, following analysis from
[9]. No other interaction terms are currently included.
The Gail model includes an interaction between (i) ethnicity and all other
risk factors, and for certain ethnic groups an interaction between (ii) age and
number of biopsies, and (iii) age at first child and number of affected first-
degree relatives (negative interaction). For example, both latter interactions are
included for white women, but they are not used for Asian women.
The BCSC model includes interactions between a woman’s age with (i) eth-
nicity, (ii) benign disease, (iii) family history (negative interaction) and (iv)
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breast density (negative interaction), by allowing for different regression coeffi-
cients in 10y intervals starting at age 40y [61].
The Rosner-Colditz model allows for interactions between: (i) BMI and du-
ration of premenopausal period (time from menarche to start of menopause) (ii)
BMI and current duration of menopausal interval, (ii) alcohol after menopause
and hormone replacement therapy, (iii) benign disease with age at menarche,
(iv) benign disease with duration of premenopause, (v) benign disease with du-
ration of menopause, (vi) height with duration of premenopause (vii) height
with duration of postmenopause.
All the models (except Tyrer-Cuzick) include interactions relating to benign
disease, but their forms are quite different. In the Gail model, for white women
the relative risk of previous biopsies is less in women older than 50y than for
younger women. In the BCSC cohort used to fit their model [61] this pattern
was not observed for proliferative disease, and for non-proliferative disease the
direction was even reversed (a larger effect for women older than 50y). In the
Rosner-Colditz model there is a positive interaction with age at menarche and a
negative interaction for the other terms (albeit none are univariately significant
in the most recent model at a 5% level [51]), suggesting an older age at menar-
che is not protective for women with benign disease. These three models have
been fitted in populations with individual-level data. Relative hazards for white
women in the Gail model were estimated using a case-control study with 2842
cases and 3146 controls, including 179 cases with a prior biopsy aged <50y and
487 cases with a prior biopsy aged 50y+ [31]. The BCSC model was fitted to a
cohort with more than 1 million women with up to 10y follow up, and included
6204 women with proliferative disease without atypia and 177 subsequent can-
cers [61]. A recent Rosner-Colditz model update included approximately 100,000
women of whom 5,246 had developed breast cancer. Benign breast disease (non-
proliferative and proliferative) was reported in approximately 18,000 women at
entry [51].
Potential interactions between benign disease and other risk factors have also
been investigated in other studies, but also with inconclusive findings. For exam-
ple, in a cohort from Nashville a negative interaction between non-proliferative
disease and age was observed, such that women diagnosed with non-proliferative
disease at an older age had lower breast cancer risks than women in the cohort
without proliferative disease [26]; this has not been evaluated in any of the four
models considered here.
Overall, due to the current lack of strong evidence to support an interaction
of benign disease with age, no such interaction is included in the Tyrer-Cuzick
model, and it assumes non-proliferative benign disease does not confer any in-
creased risk.
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4. Absolute cumulative risk assessment and calibration
4.1. Framework
It is important to be aware of the difference between using a model to project
risks and calibrating a model from a cohort where follow-up data already exists.
In the former case routine data only provides risk assuming no inter-current
mortality, and a specific adjustment needs to be made for competing mortality
(c.f. equation 3). In the latter case, inter-current deaths are known and can
be treated as part of the censoring process. This has led to different methods
for computing absolute cumulative risk, which are essential for interpreting the
model predictions, and subsequently to assess how well the model is calibrated
to the population under study. This has not been widely appreciated, and can
lead to different estimated values of expected absolute risk from the same disease
model. In this section we review some different methods for computing expected
cumulative risk under the following setup.
Assume there is a sample of i = 1, . . . , n independent individuals with data
on risk factors. The risk model evaluates each risk from current age t0 to age t,
defined as Pxi(t0i, t) or Pi(t) using shorthand notation following equation (3).
The time to breast cancer or death is subjected to right-censoring, so that one
observes T˘ = min(T1, T2, TC), where T1 is time to disease, T2 is the time to
death from other causes and TC is a right-censoring time.
An issue to contend with for computing the expected probability of breast
cancer is that the ‘at-risk’ interval should be from t0 to TC , whereas T˘ is often
used. TC is not observed when min(T1, T2) < TC and this presents difficulties as
its (conditional) distribution can be hard to determine. Calculating the expected
risk using probability of breast cancer over (t0, T˘ ) is liable to underestimate
expected risk. A solution is to use lifetable methods which are based on the
sub-hazard of breast cancer and not the probability of breast cancer, but only
need to be computed over (t0, T˘ ). We next consider these different methods in
more detail.
4.2. Expected risk based on the cumulative disease-specific hazard
function
The expected number of breast cancer cases in the cohort may be obtained
by first integrating breast cancer specific hazards over the observed follow-up
period, to obtain each individual’s cumulative hazard for breast cancer during
the period she is at risk. Formally, let Yi(t) = I(T˘i > t) denote the at-risk process
for individual i = 1, . . . , n, and h1(t | xi) = h1i(t) the disease-specific hazard
function sub-model. Then the expected number of individuals with disease (J =
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1) is
E(H) =
n∑
i=1
∫ ∞
t0i
h1i(u)Yi(u)du
=
n∑
i=1
H1i(T˘i) (11)
where
H1i(t) =
∫ t
t0i
h1i(u)du.
Equation (11) may be adapted to compute the expected number of deaths from
other causes by replacing h1 with h2, etc. Indeed, by letting h2 reflect all-cause
mortality (including breast cancers) this is equivalent to the time honoured
lifetable method to compute the expected number of deaths [39]. Thus while it
might seem surprising to base the expected number of women diagnosed with
breast cancer on the disease-specific cumulative hazard rather than the smaller
estimate of the probability of breast cancer, this method is firmly established in
lifetable and other settings (e.g. the log-rank test).
4.3. Expected risk based on cumulative incidence
The previous section is the preferred method (see below) but another approach
is to calculate expected risk using the model probability of disease allowing for
death from other causes (cumulative incidence). This is most straightforward
when the model is used in a cohort with no censoring from starting age t0 up
to age t. In this case the expected number is a summation of the conditional
cumulative incidence in (3):
E(P )(t) =
n∑
i=1
Pi(t), (12)
where Pi(t) ≡ Px(t0, t) for the i-th individual. It is extremely uncommon to
have such a dataset, and the calculation is more complicated under the most
common scenario of right censoring because we need an estimate of P{J =
1,min(T1, T2, TC) ≤ t | xi}, whereas Pi(t) estimates P{J = 1,min(T1, T2) ≤
t | xi} (see equation 3). We consider three types of censoring processes for
prospective risk calculation.
Firstly, if censoring is fixed to be to a common follow-up time for each patient
ti = t0i +A, such as A = 5 years, then
E(P )(A) =
n∑
i=1
Pi(ti0 +A). (13)
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Secondly, when the censoring time TC is variable between individuals but it
is deterministic, such as being due to variable calendar time enrolment and a
common follow-up for all i then
E(P ) =
n∑
i=1
Pi(ti0 + TCi). (14)
A third case is when the potential censoring time is unknown but is a stochastic
process with known distribution. Then one possibility is to base expected risk
on
PC(t) = ∫ t0+t
t0
h1(u | x)exp
[
−
∫ t0+u
t0
{h1(v | x) + h2(v | x)}dv
]
SC(u | x)du(15)
where SC is the survivor function for the censoring distribution. Then
E(P ) =
n∑
i=1
PCi(ti0 + T˘i). (16)
If SC is unknown then one will need to estimate it, for example by assuming
censoring is independent of risk factors x and using the Kaplan-Meier estimator
[40].
4.4. Calibration
The above methods based on cumulative disease-specific hazards or cumula-
tive incidence may be used to assess calibration by comparison of the observed
number of women with disease (O) with expected (E), both overall and in sub-
groups [37]. If it is assumed that disease is rare (this assumption is relaxed
in Section 4.7), then a test may be constructed assuming that O is generated
from a Poisson distribution, whose rate would be E if the model was perfectly
calibrated. Exact Poisson confidence intervals on O may be used to compute
a confidence interval for O/E (treating E as fixed) and determine if it covers
unity [32].
4.5. Some biased estimates of absolute risk and their effect on
calibration
Some commonly-used methods are biased, but this can be overcome using
hazard-based methods where the appropriate ‘at-risk’ interval is used. We next
consider three methods that yield biased estimates of E, the expected number
of cancers, which in turn leads to biased estimates of the observed to expected
ratio O/E.
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1. Under right censoring some studies [18, 24, 7, 54] have used cumulative
incidence as the measure of expected risk, but estimated it via
n∑
i=1
Pi(T˘i). (17)
This measure of expected risk is biased towards zero because it only com-
putes risk until the event time T˘ . For example, suppose we wish to compute
the expected number of deaths in a sample of babies over the next 200y.
If the mortality model is well calibrated but risk of death until the age
at which each person actually dies is summated (as equation 17), then
fewer deaths will be expected than the number of babies in the sample.
The correct analysis based on cumulative incidence would summate risk
of death by age 200y for each individual (c.f. equation 12). In mitigation,
the bias will be small, and will have a minimal impact on the conclusions
drawn when the event is rare.
2. In some studies it has been reported [2] that the expected number with
disease is computed as
n∑
i=1
[1− exp{−H1i(T˘i)}], (18)
i.e. summating 1 minus the net survival (the estimand for Kaplan-Meier
estimation) rather than (11). In general this is biased towards zero for the
expected number of breast cancers because the term in the summation
is less than or equal to the cumulative hazard H1i(T˘i). However, this is
a small bias if the cumulative hazard H is small since 1 − exp(−H) =
H +O(H2). Also note that 1− exp{−H1i(T˘i)} ≥ Pi(T˘i), so is less biased
than summating Pi(T˘i) (i.e. equation 17).
3. Finally, calibration of breast cancer risk has sometimes been assessed using
a fixed follow-up time for all by only including those who could be followed
up at least that long [60, 53]. This in inefficient because some data would
be excluded, and it should be used with caution when there is censoring.
For example, suppose we seek to assess calibration of 5y risk when there is
right censoring in the data, and include only those without breast cancer
who were not censored by 5y and all breast cancer cases diagnosed up to
5y. If the model is correct (and censoring is non-informative) then O/E
based on (12) will be biased. E will be too small relative to O because
some of the non-cases will have been excluded from expected risk due to
censoring, but they should have contributed to E as they would have been
counted as cases if disease had occured in them.
4.6. An unbiased estimate of expected risk
To avoid bias we recommend using E(H) to obtain the expected number with
disease. This is based on the cumulative hazard rather than probability of dis-
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ease (cumulative incidence) and has several advantages compared to E(P ) when
censoring has been handled appropriately as described in Section 4.3.
Firstly, comparing E(H) with O is a test of whether the disease-specific haz-
ard model is correct. The same method may also be used to test the competing-
mortality model. Comparing E(P ) with O is a test of whether the model for
cumulative incidence based on combining the disease risk and competing mor-
tality is correct, i.e. whether the marginal risk based on (3) is well calibrated.
This might require accurate knowledge and data on the competing risk pro-
cess, which is often not available. It is uncommon for the competing mortality
model to be as well developed as the disease risk model, which is of primary
interest to the epidemiologist. If the competing mortality model is incorrect,
but the disease model is correct, then the expected risk will be incorrect due to
an inadequate model for competing mortality. Conversely, even if the cumula-
tive incidence function risk is well calibrated, it is possible that the competing
mortality and disease model are both wrong in different ways, and just happen
to cancel each other out. Comparing the hazard sub-models separately would
identify such issues.
Secondly, when there is stochastic censoring equation (11) is easier to ap-
ply than (16) because it does not require an assumption or estimate for the
conditional censoring distribution.
Thirdly, it can be a more powerful test. For example, in an extreme example
of 200y follow-up on mortality in babies, then one would not be able to show
that a model that assigns a constant and excessively high mortality rate was
incorrect; whereas analysis based on summating the cumulative hazard of that
model to the time of each death would yield an expected number of deaths in
excess of observed.
4.7. Extensions
We end this section by describing methods to assess calibration not only for
the total population, but also in subgroups. For example, when the data are
split into ten groups by decile of the predicted risk at baseline then a test of
calibration (more generally model fit) across the groups would be akin to the
Hosmer-Lemeshow test for binary outcomes [35, 37]. To extend this strategy to
the cumulative incidence framework, we construct k = 1, . . . ,K distinct groups,
and assess whether the observed risk matches expected in each of the groups.
Then, the test statistic
χ2K−1 =
K∑
k=1
(Ok − Ek)2
Ek
,
where the expected Ek are obtained as above, will be approximately χ
2 with
K − 1 degrees of freedom under the null hypothesis of correct prediction and
calibration.
This hypothesis testing approach has limitations. Firstly, power to reject
inaccurate calibration is limited by the large number of degrees of freedom.
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Secondly, with a large enough sample size we would expect to reject model
calibration because all models are wrong, and the approach does not directly
indicate where the inaccuracies lie.
An alternative approach is to view testing calibration as special case of Pois-
son regression. Let Oi denote whether individual i = 1, . . . , n in the sample
has disease, and Ei be the expected risk based on the model. Then consider a
Poisson regression for
E(Oi | Ei) = exp{γ0 + γ1log(Ei)},
= θEγ1i
where θ = exp(γ0) and γ1 are unknown parameters. Setting γ1 = 1 then the
maximum likelihood estimate θˆ =
∑
iOi/
∑
i E provides an overall ‘calibration-
in-the-large’ parameter for the entire cohort [20]. When γ1 is also estimated
then it can be used to test for calibration across the range of expected risk (on
1 df), as well as yielding an estimate of how closely the regression line matches
observed (γ1 = 1 being ideal; 0 being not at all).
Finally, we consider when the disease is relatively common, perhaps because
focus is on a high risk group with long follow up. In this case the Poisson
distribution no longer approximates a binomial distribution. However, Poisson
regression may be valid if time is broken into shorter segments where the rare
disease assumption holds, for example by year, with each segment treated as a
‘new’ observation in the Poisson regression analysis. This approach is also useful
when assessing time-dependent calibration, and which we proceed to consider
next.
5. Time-dependent calibration
The focus of many studies has been on whether the cumulative number with
disease over a single follow-up period matches the expected number. While im-
portant, it does not assess differences through time, such as non-proportionality
of the observed to expected risk. In this section we consider techniques to assess
calibration across follow-up time, and develop new graphical methods.
5.1. Methods
One approach is simply to look at the observed and expected number of events
Nj(t) for each cause j as a counting process. The observed number is
Nˆj(t) =
∑
T˘i≤t
I(Ji = j). (19)
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The expected number, based on the cumulative hazard approach (as Section
4.2), is
Nj(t) =
n∑
i=1
∫ t
0
Yi(u)hji(u)du
=
∑
T˘i≤t
Hji(T˘i) +
∑
T˘i>t
Hji(t), (20)
so that we have extended (11) to be a function of t. One may compare observed
Nˆj(t) vs expected from (20) through follow-up time t, such as is sometimes
done to check proportional hazards [6, 33]. Cumulative pointwise (such as from
entry to time t), or interval (such as number in a year) confidence intervals may
be constructed using exact Poisson confidence intervals, or used to undertake
hypothesis tests of calibration up to or near time t.
An issue with the comparisons based on N(t) is that they depend on the
sample size and censoring distribution, so cannot be readily used to compare
between studies. To circumvent this one might consider the comparing the mean
cumulative hazard among those at risk, i.e. for t < maxi(T˘i) comparing
Hˆj(t) =
∑
T˘i≤t
I(Ji = j)
Y+(T˘i)
(21)
with its expected value
Hj(t) =
n∑
i=1
∫ t
0
Yi(u)hji(u)
Y+(u)
du (22)
where the total number at risk at time t is Y+(t) =
∑n
i=1 Yi(t). Note that equa-
tion (21) is the Nelson-Aalen estimator of the cumulative hazard [40]. Equation
(22) is the expected cumulative hazard based on the breast cancer risk model
and observed at-risk process. Time-dependent assessment of the observed to
expected risk can be based on Hˆj(t) vs Hj(t) across follow-up time t. Here we
treat Hj(t) as fixed and use the usual confidence intervals for the Nelson-Aalan
estimator Hˆj(t) at different times, from which the hypothesis of calibration at
a particular time t can also be assessed.
Other functionals of Hˆj(t) and Hj(t) might also be used for assessment of cal-
ibration across time. Arguably the most common functional used in applications
is the ‘net’ risk
S(t) = 1− exp{−H(t)},
which is often estimated as 1 minus the Kaplan-Meier estimator [40]. There are
two options for calculating the expected risk. The first is a mean from the entire
cohort at baseline
S
(A)
j (t) = n
−1
n∑
i=1
[1− exp{−Hji(t)}]. (23)
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The second is to use the mean hazard in those still at risk at time t through
S
(B)
j (t) = 1− exp{−Hj(t)} (24)
and (22).
A disadvantage of the cumulative hazard (22) and net risk (23,24) is that
interpretation of the component terms is not straightforward in relation to the
observable risk in equation (2). However, if we weight (21) by the proportion at
risk using the Kaplan-Meier estimator Sˆ(t) for all-cause survival (i.e. the survival
endpoint is disease or death), then we recover an estimator of the cumulative
incidence function through
Fˆj(t) =
∑
T˘i≤t
I(Ji = j)
Y+(T˘i)
Sˆ(T˘i), (25)
and inference may be based on estimates of its variance [40]. Expected risk may
be obtained from
F
(A)
j (t) = n
−1
n∑
i=1
Pi(t), (26)
or the mean expected risk at each t over the n individuals.
5.2. Summary
Our recommendation is to focus on comparisons only involving the disease-
specific hazard to assess O vs E through follow-up time t. For exploratory plots
we prefer use of the cumulative hazard comparison of (22) with (21). There are
several reasons for these recommendations.
Firstly, as for overall calibration, the method may be used to assess the
disease risk and competing mortality sub-models separately. The cumulative
hazard analysis extends quite naturally a total number of events comparison,
but avoids dependence on the censoring distribution.
Secondly, focusing on the hazard leads to using the observed at-risk process
to calculate expected risk, which appears to be a more robust method to assess
model calibration than only using a risk assessment estimate on everyone at
baseline. For instance, if those censored or lost to follow-up are more likely to be
at higher predicted risk at entry, then estimates of their expected risk will differ,
and so comparison of expected risk between methods based on using the at-risk-
process or everyone at baseline is a way to assess whether the censoring process
was associated with predicted risk. In general terms this issue has parallels with
relative survival, where one might consider the Ederer-I approach (mean risk)
or the Ederer-II approach (use the at-risk process) [55].
Thirdly, a statistical advantage of the cumulative hazard compared to the
cumulative incidence function is that it may have a smaller variance because
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it does not require an assumption or estimation of all-cause survival (equation
25).
Finally, in the exploratory plots when the aim is to assess calibration of a
risk model, then differences between the observed to expected cumulative haz-
ard seem easier to interpret than the other methods. In contrast, the cumula-
tive incidence function weighs the cumulative hazard by all-cause survival. The
component terms have a natural interpretation, but the observed to expected
comparison is perhaps less easy to interpret for assessing calibration than cu-
mulative cause-specific hazards, because changes could be due to either lack of
calibration in the disease or competing mortality models. Kaplan-Meier estima-
tion transforms the cumulative hazard through 1−exp(−H), so that differences
between large cumulative hazards are downweighted. This makes changes in
the calibration plot with time less easy to relate to calibration at the hazard
level. For example, it is easier to assess whether the hazard function is constant
through time by plotting the Nelson-Aalan estimate of the cumulative hazard,
than by plotting 1 minus the Kaplan-Meier estimator.
6. Example
6.1. Data
We have previously reported an evaluation using the Tyrer-Cuzick model in
a cohort from Washington state USA [13]. Between 1996 and 2013, 132 139
women aged 40-73y completed a risk questionnaire and had a measure of breast
density taken at entry. They were followed up beginning 6-months after the entry
mammogram to the earliest of diagnosis of invasive breast cancer or censoring.
Women were censored due to disenrollment (n=62 331, 48.2%), end of follow-
up (n=48 317, 37.3%), age 75y (n=15 827, 12.2%), death from other causes
(n=2328, 1.8%) or ductal carcinoma in situ (n=637, 0.5%). Only aggregate
data on competing risk causes were made available for analysis, so we were
unable to apply methods that require individual-level data about the cause of
censoring.
6.2. Calibration
A total of 2699 breast cancers were observed (O), and based on our preferred
method (equation 11) 2757 were expected (E), yielding O/E 0.98 (95%CI 0.94-
1.02). We next consider application of incorrect methods discussed in section
4.5.
A first biased assessment is cumulative incidence over a 5y fixed-time horizon
by using all the cases that were diagnosed in the 5y period and all non-cases
at risk for 5y or more. It we calculate the expected 5y risk in those who are
at risk at 5y then E = 877 against an observed O = 1157 (O/E = 1.32). A
second biased method is to summate expected cumulative incidence to the last
follow-up for each individual (equation 17), yielding E = 2605 and O/E = 1.04
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(95%CI 1.00 to 1.08). A third biased method is to follow equation (18) and
summate the absolute net risks, which gives expected number E = 2679 (O/E
= 1.00).
It also instructive to repeat the above methods in a high-risk group (> 8%
ten-year net risk) where greater differences between the methods to calculate E
will occur. The Tyrer-Cuzick model with mammographic density identified 4645
women to be in this group, and 273 breast cancers were subsequently diagnosed.
Based on the preferred method (11) we find E = 349, so that O/E = 0.78
(95%CI 0.69-0.88), indicating that the model over predicted the high risk group.
If instead (18) was used then E = 324 and O/E = 0.84 (95%CI 0.75-0.95).
Based on (17) we find E = 310 so that O/E = 0.88 (95%CI 0.78-1.00), where
the 95%CI covers unity. Thus the correct analysis showed a lack of calibration
that would not be seen so clearly with the biased methods.
This analysis shows the method to calculate expected risk can cause practi-
cally important differences in interpretation of risk model calibration, particu-
larly for high-risk groups.
6.3. Time-dependent calibration plots
Time-dependent calibration was assessed using the methods in Section 5. We
present results from overall model calibration (Figure 2) and in the highest and
lowest risk deciles (Supplementary Figures S1 and S2) following [13].
Overall the model appeared well calibrated throughout follow-up time. As
follow-up started at six months, the expected hazard in the first year was much
lower than the second year of followup. Figure 2a shows the model did not
adequately take into account the effect of removal of a pool of cancers diag-
nosed at entry. However, subsequently the model tracked the observed number
quite closely. Figures 2c,d show respectively the Nelson-Aalan and Kaplan-Meier
curves. The corresponding observed to expected plots in Figures 2e,f are virtu-
ally identical using the expected risk based on those still at risk. There is also
very little difference between the two methods to obtain expected risk using the
Kaplan-Meier approach, which indirectly confirms that censoring was unrelated
to risk assessment.
The same plots were used to assess high and low risk groups. Supplementary
Figure S1 considers women who were in the highest predicted risk decile at entry.
As noted in Section 6.2, there is some evidence of over-estimation from the model
for this group. However, the observed to expected plots in Supplementary Figure
S1e,f show a fairly constant pattern across time, with no discernible difference
between Nelson-Aalan or Kaplan-Meier comparisons. Supplementary Figure S2
shows calibration of the bottom decile, where calibration appears reasonable
through follow up time, albeit with a suggestion that the model had a tendency
to under estimate risks.
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6.4. Regression analysis
The above analysis suggests that the risk model was calibrated overall in the
cohort, but tended to overestimate risk in those predicted at highest risk; it
over-estimated risk in the first year due to omitting screen-detected cases, but
the risk predictions thereafter were stable with greater follow-up time. All these
aspects may be jointly tested through a Poisson regression model. The model
was fitted with an exponential link function. The log hazard per year (or until
the event or censoring if in that year) was included as an offset term, and
calibration coefficients were estimated for (i) overall lack of calibration in the
first year, (ii) stability of calibration from year two onward (follow-up year), and
(iii) 10y risk categories from the model as previously defined (<2%, 2 to <3%,
3 to < 5%, 5 to < 8%, ≥ 8%; with 2-3% group as the reference category) [13].
Results are shown in Table 2, taking the exponent of the estimated model
parameter to give a calibration coefficient where unity indicates ideal calibration.
They confirm the earlier analysis. The risk model over estimated risk in the first
year by a factor of two (calibration coefficient 0.50, 95%CI 0.40-0.63), which is
due to the expected short-term reduction in risk following a negative screen.
There was no loss in calibration subsequently (calibration 1.00, 95%CI 0.99-
1.01). The highest risk category (10y risk ≥ 8%) exhibited evidence of over-
estimation of risk relative to the reference average-risk category (calibration
overall 0.80, 95%CI 0.69 - 0.92, i.e. including the intercept), and likewise there
was some under-estimation in the lowest-risk group (overall test for calibration
across the five groups likelihood-ratio χ2 = 48.6, df=4).
7. Conclusion
In this paper we reviewed the statistical foundations of a model to evaluate
breast cancer risk at different follow-up times. This model, and corresponding
computer program, synthesise findings from many scientific studies by combin-
ing risk factors into a hybrid genetic segregation and regression model. The
model has been used to guide entry criteria into prevention trials [22], and is
recommended by several organisations to guide preventive and early detection
strategies, including the American Cancer Society to help determine eligibility
for supplemental breast magnetic resonance imaging [56].
We developed new graphical methods for looking at calibration over follow-
up time that can be combined with Poisson regression analysis. The impact of
using the different methods to assess the calibration of cumulative absolute risk
was reviewed. Different methods to account for competing risks when assessing
risk model calibration have been used. We note that, given the diversity of
methods in use and potential impact on findings, it is important when presenting
calibration findings that a detailed description of the method for expected risk
is also given [1].
There are opportunities to refine and improve the current risk model. Other
factors are known to affect the risk of breast cancer, but most have some dif-
ficulties for inclusion in a relatively simple model. Using weight change from
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age 20 or weight at a young age in addition to current weight does appear to
improve risk assessment to some extent [36], but requires accurate recall of pre-
vious weight. Alcohol consumption is a well documented risk factor [34], but
underestimation of consumption is well known and it is not clear how best to
allow for this. The differing roles of weight in the pre- and postmenopausal pe-
riods also needs further investigation [57]. Physical activity and dietary factors
are also known to affect risk [49, 70], but identification of the key factors and
simple accurate measures of these currently present difficulties. Levels of oe-
strogens and testosterone may also be important especially for postmenopausal
women, but these require a blood sample and are not routinely available [71].
Ethnic differences in breast cancer risk are also well documented - notably in
the US lower risks in Hispanics and Asians [8]. However it is unclear as to how
these are related to differences in the known risk factors in the model, so would
not need model recalibration, or whether there are intrinsic ethnic differences
which require use of a separate baseline hazard function, and possibly separate
risks for the known factors. Differences between recent migrants and established
individuals are also known to exist and complicate any model adjustments [38].
Adding breast density has substantially improved the model, and might be ex-
tended by considering longitudinal measurements of density and features in the
mammogram other than simply breast density, where more complex algorithms
may be able to extract more risk information [66]. The polygenic (SNP) risk
score is steadily being improved as more SNPs are added, but this is easily
accommodated as all that is required is the relative risk. A bigger challenge
is to accurately account for interactions between risk factors. Our model was
developed by synthesizing risks for individual factors from large overviews of
many studies, and large datasets which contain all the factors will be needed to
fully explore interactions. These are not currently available but are likely to be
so soon, as the risk factors used in our model are currently being collected in
several large cohorts of patients.
In conclusion, we are gradually moving towards an era of precision medicine,
where disease treatment, early detection and prevention strategies will depend
on risk assessment. The accuracy of risk models will underpin this approach.
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Fig 1. Volumetric percentage density vs age and body mass index (BMI), with joint non-
parametric smooths (line —). Taken from [12].
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Table 1
Summary of risk factor parameters in model.
Category Hazard ratio Mean risk Reference category
(a) Classic risk factors
Menopause age (y) per 5y 1.14 1.08 45-49y
Menarche age (y) <11 1.16 1 13y
11 1.07
12 1.07
13 1
14 0.98
15 0.93
16 0.88
17 or older 0.81
Height (m) <1.6 1 1.1 <1.6m
1.6-1.7 1.05+2*(height-1.6)
1.7 or taller 1.24
Body mass index <21 1 1.24 <21
(kg/m2) 21 to <23 1.14
(post-menopausal only) 23 to <25 1.15
25 to <27 1.26
27 or more 1.32
Age at 1st Nulliparous 1 1 Nulliparous
childbirth (y) <17-19 0.74
20-24 0.77
25-29 0.87
30-34 1.01
35+ 1.11
Menopausal Not current 1 1 Not current
hormone therapy Estrogen-only (current) 1.4
Combined (current) 2
Benign disease Non-proliferative / none 1 1 None
Proliferative (usual type) 2
Atypical hyperplasia 4
Lobular carcinoma in situ 8
(b) New in v8
Breast density residual Visual asssessment scale 1.4 per SD 1 Average density
(age 40y+) BI-RADS density 1.4 per SD (age and BMI
Volumetric percentage 1.4 per SD adjusted)
SNPs Continuous Input 1 Average woman
Footnote: SD, standard deviation; SNP, single nucleotide polymorphism risk score.
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Table 2
Calibration assessment: univariate and Poisson regression (adjusted for variables listed)
calibration coefficient estimates with 95% Wald confidence intervals.
Term n O E O/E [univariate] O/E (95%CI) [adjusted]
Overall (intercept) 132139 2699 2757 0.98 1.05 (0.94-1.16)
Follow-up time
Year 1 132139 87 178 0.49 0.50 (0.40-0.63)
Year 2+ (time) 123830 2612 2579 1.01 1.00 (0.99-1.01)
10y Risk group
<2% 53436 641 548 1.12 1.17 (1.00-1.25)
2 to <3% 33269 627 603 1.04 1
3 to <5% 29477 779 784 0.99 0.96 (0.86-1.07)
5 to <8% 11312 379 473 0.80 0.78 (0.68-0.88)
8%+ 4645 273 349 0.78 0.76 (0.66-0.88)
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Fig 2. Overall calibration of the breast cancer risk model. (a) Observed (95%CI) vs ex-
pected number of breast cancers diagnosed for each year of follow-up, (b) cumulative observed
(95%CI) vs expected number of breast cancers diagnosed; (c) observed (Nelson-Aalan, 95%CI)
vs expected cumulative hazards; (d) observed (Kaplan-Meier, 95%CI) vs expected (obtained
via two methods) net risks; (e) Observed divided by Expected cumulative hazard (95%CI); (f)
Observed divided by expected net risk (obtained via two methods) with 95%CI only for the
expected risk based on baseline risk assessment.
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Fig S1. Calibration of top decile of 10y predicted risk (>5.4% 10y net risk). (a) Observed
(95%CI) vs expected number of breast cancers diagnosed for each year of follow-up, (b) cu-
mulative observed (95%CI) vs expected number of breast cancers diagnosed; (c) observed
(Nelson-Aalan, 95%CI) vs expected cumulative hazards; (d) observed (Kaplan-Meier, 95%CI)
vs expected (obtained via two methods) net risks; (e) Observed divided by Expected cumulative
hazard (95%CI); (f) Observed divided by expected net risk (obtained via two methods) with
95%CI only for the expected risk based on baseline risk assessment.
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Fig S2. Calibration of bottom decile of 10y predicted risk (<1.1% 10y net risk). (a) Ob-
served (95%CI) vs expected number of breast cancers diagnosed for each year of follow-up,
(b) cumulative observed (95%CI) vs expected number of breast cancers diagnosed; (c) observed
(Nelson-Aalan, 95%CI) vs expected cumulative hazards; (d) observed (Kaplan-Meier, 95%CI)
vs expected (obtained via two methods) net risks; (e) Observed divided by Expected cumulative
hazard (95%CI); (f) Observed divided by expected net risk (obtained via two methods) with
95%CI only for the expected risk based on baseline risk assessment.
